Alfuzosin hydrochloride, (S)- | 183658-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Alfuzosin hydrochloride, (S)-
• 英文别名: (2S)-N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
• CAS: 183658-26-6
• 化学式: C19H28ClN5O4
• 分子量: 425.9
• InChiKey: YTNKWDJILNVLGX-UQKRIMTDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE
  申请人：Torralva Medical Therapeutics LLC

  公开号：US20220160704A2

  公开（公告）日：2022-05-26

  Pharmaceutical compositions are provided including therapeutically effective amounts of an α1 adrenergic receptor antagonist, together with one or more of (1) a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and/or cholinergic agents. (4) a combined alpha-1 adrenergic antagonist and anticholinergic (e.g. droperidol), (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure/membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and/or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and/or respiratory depression) arising from intentional or accidental opioid or opiate exposure, involving administering to the subject such a pharmaceutical composition. Methods of providing analgesia with a modified side effect profile to reduce risk of WCS or respiratory effects are also provided.
• [EN] CONTROLLED RELEASE FORMULATIONS OF ALFUZOSIN<br/>[FR] FORMULATIONS D'ALFUZOSINE À LIBÉRATION CONTRÔLÉE
  申请人：AUROBINDO PHARMA LTD

  公开号：WO2008102235A1

  公开（公告）日：2008-08-28

  [EN] The present invention relates to controlled release formulations comprising an alpha-adrenergic receptor antagonist. More particularly, the present invention relates to controlled release matrix formulation comprising alfuzosin hydrochloride and a combination of hydrophilic and hydrophobic polymers prepared by direct compression.
  [FR] La présente invention concerne des formulations à libération contrôlée comprenant un antagoniste du récepteur alpha-adrénergique. De manière plus particulière, la présente invention concerne une formulation de matrice à libération contrôlée comprenant du chlorhydrate d'alfuzosine et une combinaison de polymères hydrophiles et hydrophobes préparés par compression directe.